Gritstone Oncology Inc

Gritstone bio, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded by Andrew Allen, Timothy Chan, Mark Cobbold, Graham Lord, Naiyer Rizvi and Jean-Charles Soria in August 2015 and is headquartered in Emeryville, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Gritstone Oncology reports strong financials and promising advancements in immunotherapy

Gritstone Oncology Inc showcases financial stability, progress in cancer immunotherapy, and advancements in infectious disease programs. Challenges include data requirements for ongoing studies, while opportunities lie in upcoming data presentations and exploring novel vaccine concepts.

Gritstone Oncology excels in Q1 with promising GRANITE program and samRNA advancements

Gritstone Oncology's Q1 2023 earnings call highlighted strong financials, progress in the GRANITE program, and advancements in the samRNA platform. Challenges include endpoint selection for Phase 3 study and managing pseudo progressors. Opportunities lie in combining immunotherapies for KRAS mutations and exploring adjuvant settings.

Gritstone Oncology reports positive Q1 results and eyes market expansion

Gritstone Oncology's Q1 2024 performance showcased positive outcomes in the GRANITE program and financial stability through strategic funding.
The company's strengths lie in promising immune responses, encouraging PFS data, and a proactive approach to clinical program advancement.
Challenges include data gaps in patient groups and uncertainties around future consortium data, while opportunities abound in market expansion and upcoming data releases.
Overall, Gritstone Oncology's focus on innovative cancer vaccine programs and financial prudence positions them well for future growth and clinical success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

-- Expert in virology, immunology and vaccine development's appointment effective August 12 -- -- Expert in virology, immunology and vaccine development's appointment effective August 12 --

Gritstone Appoints Dr. Lawrence “Larry” Corey to its Board of Directors

Gritstone bio Inc. (NASDAQ:GRTS ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants George MacDougall - Director, Investor Relations and Corporate Communications Andrew Allen - Co-Founder, President, CEO and Director Vassiliki Economides - Executive VP and CFO Karin Jooss - Head of Research and Development Conference Call Participants Marc Frahm - Cowen Tom Shrader - BTIG Sean Lee - H.C. Wainwright Corinne Jenkins - Goldman Sachs Umer Raffat - Evercore Operator Welcome to Gritstone bio Second Quarter 2022 Conference Call.

Gritstone bio Inc. (GRTS) CEO Andrew Allen on Q2 2022 Results - Earnings Call Transcript

Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 15% and 117.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Gritstone bio Inc. (GRTS) Reports Q2 Loss, Tops Revenue Estimates

Conference call to occur at 4:30pm ET on August 4 Conference call to occur at 4:30pm ET on August 4

Gritstone to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 4, 2022

Microsatellite stable colorectal cancer patients who had a molecular response who took GRANITE combination exceeded mOS of 18 months and mOS has not yet been reached. The global market opportunity for colorectal cancer is expected to reach $18.5 billion by 2023.

Gritstone bio: Potential To Advance Colorectal Cancer Treatment

Gritstone bio is developing targeted immunotherapies for infectious diseases and cancer by enhancing the body's immune system to recognize and destroy unhealthy cells by targeting specific antigens. Gritstone has developed a self-amplifying mRNA COVID-19 vaccine, as well as an HIV candidate and several oncology programs.

Gritstone bio: Investing In A Premium mRNA Technology At A Discounted Valuation

-- Results, which were previously pre-printed in bioRxiv, show Gritstone's second-generation self-amplifying mRNA (samRNA) vaccine candidate drove broad neutralizing antibodies, T cell responses and offered protection against SARS-CoV-2 infection in rhesus macaques -- -- Neutralizing antibody responses were induced at up to a 10-fold lower dose than first-generation mRNA vaccines --

Gritstone Announces Results from Preclinical Study of its Self-amplifying mRNA (samRNA) Vaccine Against SARS-CoV-2 Published in Nature Communications

EMERYVILLE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced that the company has been certified as a Great Place to Work by the Great Place to Work® Institute. Gritstone earned this highly desirable credential based on a comprehensive set of ratings provided by its employees in an anonymous survey. The award is based entirely on what current employees say about their experience working at Gritstone bio.

Gritstone Earns 2022 Great Place to Work Certification™

Kaival Brands Innovations Group

OpGen

Check these 3 penny stocks out for your watchlist right now The post Best Penny Stocks to Buy in June? 3 to Watch Today  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy in June? 3 to Watch Today

EMERYVILLE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced that Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer of Gritstone, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference, which is being held virtually and in-person from May 23-26, 2022.

Gritstone to Participate in H.C. Wainwright Global Investment Conference

-- Clinical programs continue progressing, with multiple Phase 2 data catalysts from neoantigen oncology vaccine programs and additional human data evaluating self-amplifying mRNA (samRNA) vaccines against viruses expected over the next 18 months -- -- Recent presentations reinforce expertise in vaccine design and delivery and potential of Gritstone's platform technologies in oncology and infectious diseases --

CORRECTION -- Gritstone Reports First Quarter 2022 Financial Results and Provides Business Update

-- Translational immunology data and cassette design capabilities enabled development of an optimized, KRAS-specific version of “off-the-shelf” vaccine candidate now in Phase 2 (SLATE-KRAS) -- -- GRANITE data (individualized neoantigen-based therapeutic vaccine program) support circulating tumor DNA (ctDNA) response as a predictor of overall survival in metastatic colorectal cancer --

Gritstone Presentations at AACR Further Support Expertise in Neoantigen Vaccine Design and Delivery

Adagene

Amgen

Checkmate Pharmaceuticals

Eli Lilly

Given that developing biotechnology companies are more susceptible to swings in stock price than established ones, investors might want to keep an eye on happenings at next month's American Association for Cancer Research Annual Meeting in New Orleans. Of the eight public companies that will discuss clinical trial results, half qualify as small caps or lesser.

Investors Hoping for News at Cancer Meeting That Will Boost Share Prices

-- Four trials now initiated for CORAL, Gritstone's second-generation COVID-19 program focused on delivering T cell enhanced self-amplifying mRNA (samRNA) vaccines -- -- Oncology programs advancing as planned, with individualized neoantigen-based immunotherapy, GRANITE, now in a Phase 2/3 trial in newly diagnosed metastatic, microsatellite-stable colorectal cancer (MSS-CRC) patients and a Phase 2 trial of mutant KRAS-focused “off the shelf” neoantigen-based immunotherapy SLATE ongoing --

Gritstone Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Corporate Updates

-- Oral presentation to discuss how translational immunology data enabled iterative development of an optimized, KRAS-specific version of “off-the shelf” vaccine candidate; the optimized version is now in Phase 2 testing for solid tumor patients -- EMERYVILLE, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced three abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13, 2022, in New Orleans, Louisiana. In the poster presentations, Gritstone representatives will review data from individualized neoantigen program, GRANITE, and the “off-the-shelf" neoantigen vaccine program, SLATE. In the oral presentation, Christine D Palmer, PhD will discuss how immunodominant human T cell responses to tumor specific neoantigens presented by the same HLA in a first-generation construct informed development of a second-generation candidate that exhibits immunogenic superiority over version 1 in preclinical models within SLATE. This optimized candidate, SLATE-KRAS, exclusively includes KRASmut epitopes and is now in Phase 2 testing in solid tumor patients.

Gritstone Announces Three Presentations for Tumor-Specific Neoantigen (TSNA) Oncology Programs, GRANITE and SLATE, at the 2022 AACR Annual Meeting

EMERYVILLE, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer will participate in the “Infectious Disease” panel at the Cowen 42nd Annual Health Care Conference, which is being held virtually from March 7 to 9.

Gritstone to Participate in Cowen 42nd Annual Health Care Conference

Sorrento Therapeutics Inc

These unloved biotechs have enormous upside potential.

2 Beaten-Down Biotech Stocks That Could Make You Filthy Rich

-- Phase 2/3 GRANITE-CRC-1L trial has registrational intent -- -- Updated data from Phase 1/2 trial in end-stage metastatic MSS-CRC further support the association of circulating tumor DNA (ctDNA) reduction with extended overall survival --

Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)

Gritstone bio Inc (NASDAQ: GRTS) has shared data from the first cohort (10 µg dose) of the Phase 1 booster trial of self-amplifying mRNA (samRNA) COVID-19 vaccine. The data demonstrated strong neutralizing antibody responses to Spike and robust CD8+ T cell responses.

Gritstone Bio's COVID-19 Booster Dose Shows Early Neutralizing Antibody Responses

EMERYVILLE, Calif., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that Gritstone management will participate in the following upcoming investor conferences in January.

Gritstone Announces Presentations during Three Upcoming Investor Conferences

-- Clare Fisher, accomplished corporate and business development executive and current svp of business development and mergers & acquisitions at BeiGene, will join the Board effective January 1, 2022 -- -- Judith J. Li, partner at Lilly Asia Ventures, will depart the Board effective January 1, 2022 --

Gritstone Announces Changes to Its Board of Directors

Gritstone bio Inc (NASDAQ: GRTS) and Coalition for Epidemic Preparedness Innovations (CEPI) have expanded their agreement to support the development of a self-amplifying mRNA (SAM) vaccine designed to tackle the Omicron COVID-19 variant.  CEPI will provide up to $5 million in additional funding to conduct a Phase 1 clinical trial of Gritstone's Omicron vaccine candidate in South Africa, where a CEPI-funded trial of Gritstone's Beta variant COVID-19 vaccine is due to begin shortly.

Gritstone bio, CEPI Expand COVID-19 Vaccine Agreement to Combat Omicron Variant

EMERYVILLE, Calif. and OSLO, Norway, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, and CEPI, the Coalition for Epidemic Preparedness Innovations, today announced the expansion of their agreement in order to support the development of a self-amplifying mRNA (SAM) vaccine designed to tackle the Omicron COVID-19 variant. CEPI will provide up to $5 million in additional funding to conduct a Phase 1 clinical trial of Gritstone's Omicron vaccine candidate in South Africa, where a CEPI-funded clinical trial of Gritstone's Beta variant COVID-19 vaccine is due to begin shortly. The SARS-CoV-2 T cell epitopes (TCEs) administered within Gritstone's SAM COVID-19 vaccines are minimally impacted by mutations found within the Omicron variant, reinforcing the platform's potential to address both Omicron and future variants of concern.

Gritstone bio and CEPI Expand Vaccine Agreement to Tackle Omicron Variant

Investors need to pay close attention to Gritstone (GRTS) stock based on the movements in the options market lately.

Implied Volatility Surging for Gritstone (GRTS) Stock Options

Gritstone bio Inc (NASDAQ: GRTS) announced that the SARS-CoV-2 T cell epitopes (TCEs) administered within its self-amplifying mRNA (SAM) COVID-19 vaccines are minimally impacted by the Omicron (B.1.1.529) variant. Gritstone says that its second-generation SARS-CoV-2 vaccine platform delivers a stabilized Spike protein and highly conserved TCEs derived from other SARS-CoV-2 viral genes, offering potentially more durable protection and broader immunity against the variants.

News for Gritstone Oncology Inc Stock (GRTS)